全文获取类型
收费全文 | 3965篇 |
免费 | 193篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 166篇 |
妇产科学 | 83篇 |
基础医学 | 431篇 |
口腔科学 | 45篇 |
临床医学 | 242篇 |
内科学 | 1099篇 |
皮肤病学 | 122篇 |
神经病学 | 341篇 |
特种医学 | 93篇 |
外科学 | 665篇 |
综合类 | 23篇 |
预防医学 | 169篇 |
眼科学 | 25篇 |
药学 | 266篇 |
中国医学 | 4篇 |
肿瘤学 | 375篇 |
出版年
2024年 | 3篇 |
2023年 | 37篇 |
2022年 | 10篇 |
2021年 | 38篇 |
2020年 | 33篇 |
2019年 | 33篇 |
2018年 | 55篇 |
2017年 | 46篇 |
2016年 | 55篇 |
2015年 | 63篇 |
2014年 | 71篇 |
2013年 | 78篇 |
2012年 | 343篇 |
2011年 | 337篇 |
2010年 | 98篇 |
2009年 | 98篇 |
2008年 | 292篇 |
2007年 | 291篇 |
2006年 | 299篇 |
2005年 | 343篇 |
2004年 | 313篇 |
2003年 | 288篇 |
2002年 | 244篇 |
2001年 | 172篇 |
2000年 | 218篇 |
1999年 | 100篇 |
1998年 | 44篇 |
1997年 | 18篇 |
1996年 | 15篇 |
1995年 | 10篇 |
1994年 | 16篇 |
1993年 | 9篇 |
1992年 | 8篇 |
1991年 | 9篇 |
1990年 | 14篇 |
1989年 | 6篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1965年 | 1篇 |
1963年 | 1篇 |
1943年 | 1篇 |
排序方式: 共有4167条查询结果,搜索用时 15 毫秒
51.
Adan Hernandez Chunfeng Tan Florian Plattner Aric F. Logsdon Karine Pozo Mohammad A. Yousuf Tanvir Singh Ryan C. Turner Brandon P. Luke-Wold Jason D. Huber Charles L. Rosen James A. Bibb 《Molecular brain》2018,11(1):64
Direct or indirect exposure to an explosion can induce traumatic brain injury (TBI) of various severity levels. Primary TBI from blast exposure is commonly characterized by internal injuries, such as vascular damage, neuronal injury, and contusion, without external injuries. Current animal models of blast-induced TBI (bTBI) have helped to understand the deleterious effects of moderate to severe blast forces. However, the neurological effects of mild blast forces remain poorly characterized. Here, we investigated the effects caused by mild blast forces combining neuropathological, histological, biochemical and neurophysiological analysis. For this purpose, we employed a rodent blast TBI model with blast forces below the level that causes macroscopic neuropathological changes. We found that mild blast forces induced neuroinflammation in cerebral cortex, striatum and hippocampus. Moreover, mild blast triggered microvascular damage and axonal injury. Furthermore, mild blast caused deficits in hippocampal short-term plasticity and synaptic excitability, but no impairments in long-term potentiation. Finally, mild blast exposure induced proteolytic cleavage of spectrin and the cyclin-dependent kinase 5 activator, p35 in hippocampus. Together, these findings show that mild blast forces can cause aberrant neurological changes that critically impact neuronal functions. These results are consistent with the idea that mild blast forces may induce subclinical pathophysiological changes that may contribute to neurological and psychiatric disorders. 相似文献
52.
A case of dysgraphia induced by sertraline and a review of official spontaneous adverse reaction databases
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
53.
54.
55.
Salvatore Fundarò M.D. Andrea Spallanzani M.D. Dr. Elio Ricchi M.D. Alfonso Carriero M.D. Stefano Perrone M.D. Giulia Giusti M.D. Alberto Giannetti M.D. GianCarlo De Bernardinis M.D. 《Diseases of the colon and rectum》1998,41(1):111-114
AIM: We present a case of squamous-cell carcinoma developing within perianal lichen planus. This is a chronic or recurrent cutaneous and/or mucosal dermatosis affecting less than 1 percent of the population. Neoplastic degeneration of cutaneous lichen planus is rare; only one case of squamous-cell carcinoma developing within perianal lichen planus has been described up until now in the international literature. CASE REPORT: Our case involved a 68-year-old woman with chronic, long-term lichen planus spreading all over the vulva and perianal region and the mucosa of the anal canal, where squamous-cell carcinoma developed within the perianal lichen planus. Treatment consisted of wide, circular excision of the perianal skin and mucosectomy of the anal canal up to as far as 1 cm above the dentate line. Reconstruction was performed by means of two V-Y bilateral subcutaneous flaps. CONCLUSION: Wide excision was performed not only to remove the squamous-cell carcinoma but also the lichen planus to prevent recurrence of metachronous or synchronous squamous-cell carcinoma. Follow-up at one year after surgery showed no local recurrence of either lichen planus or squamous-cell carcinoma, which suggests that surgical removal should be the therapy of choice for long-term, chronic perianal lichen planus that has proved to be resistant to medical therapy. 相似文献
56.
In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease 总被引:10,自引:0,他引:10
Munro JM; Freedman AS; Aster JC; Gribben JG; Lee NC; Rhynhart KK; Banchereau J; Nadler LM 《Blood》1994,83(3):793-798
The B-lymphocyte/accessory-cell activation antigen B7 (BB1) has been shown in vitro to stimulate T-lymphocyte proliferation and cytokine production via CD28 present on the latter cells. In this study, benign lymphoid tissues, lymphomas, and extralymphoid inflammatory sites were examined immunohistochemically using anti-B7 and other relevant monoclonal antibodies. B7 was expressed by benign transformed germinal center B cells, as it was by B cells of follicular lymphomas. B7 was also expressed by a subpopulation (a mean of 31% to 65%) of macrophages and dendritic cells in a variety of lymphoid tissues. It was present in abundance on all macrophages constituting sarcoid granulomas in lymph nodes. In extralymphoid inflammation, 17% to 35% of macrophages expressed B7 only weakly. Cases of Hodgkin's disease showed expression of B7 by the majority of Reed-Sternberg cells or malignant mononuclear variants, a phenomenon that potentially contributes to the lymphocytic accumulation that is a feature of this condition. CD28+ T cells were seen in all areas where T cells were present. B7+ and CD28+ cells colocalized in, for example, lymphoid follicles, lymph node paracortex, sarcoid granulomas, and Hodgkin's disease tissue, indicating a potential for cellular interaction via these molecules at these sites. 相似文献
57.
New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Javid Gaziev MD Antonella Isgrò MD Alessia Francesca Mozzi PhD Aurèlie Petain PhD Laurent Nguyen MD Cristiano Ialongo MD PhD Vincenzo Dinallo PhD Pietro Sodani MD Marco Marziali MD Marco Andreani PhD Manuela Testi PhD Katia Paciaroni MD Cristiano Gallucci MD Gioia De Angelis MD Cecilia Alfieri MD Michela Ribersani MD Guido Lucarelli MD 《Pediatric blood & cancer》2015,62(4):680-686
58.
Pozzilli P Crinò A Schiaffini R Manfrini S Fioriti E Coppolino G Pitocco D Visalli N Corbi S Spera S Suraci C Cervoni M Matteoli MC Patera IP Ghirlanda G;IMDIAB Group 《Diabetes technology & therapeutics》2003,5(6):965-974
In a pilot study, the metabolic effects of continuous subcutaneous insulin infusion (CSII) versus intensive subcutaneous insulin therapy (ISIT) started at diagnosis in patients with Type 1 diabetes and continued for a 2-year period were evaluated and compared. Twenty-three patients (between 12 and 35 years old, mean +/- SD 18.4 +/- 9 years) were randomized into two treatment groups (CSII vs. ISIT), and both received supplemental nicotinamide (NA), 25 mg/kg of body weight. CSII was started immediately after admission to the hospital. Parameters of metabolic control [insulin dose, hemoglobin A1c (HbA1c), and C-peptide] were evaluated for a 2-year follow-up period. Data are presented for a total of 19 patients who remained in the study for its duration. Two years after diagnosis, mean +/- SD HbA1c was 6.3 +/- 0.5% and 6.2 +/- 0.3% for the CSII and ISIT groups, respectively (p=not significant). Compared with baseline values, an increase of baseline C-peptide of 38% for the CSII group and 27% for the ISIT group was observed; however, the difference between the groups was not significant. The insulin requirement for the entire duration of the study, but not at entry and 3 months, was significantly higher in CSII compared with ISIT patients (0.62 +/- 0.4 IU/kg/day vs. 0.3 +/- 0.4 IU/kg/day, respectively; p<0.01). After trial completion patients on CSII continued with this mode of therapy. Implementation of CSII as well as ISIT at diagnosis of Type 1 diabetes and continuation for 2 years thereafter achieved similar and optimal metabolic control, but more insulin was required with the CSII group. Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis. 相似文献
59.
Hanny Al-Samkari Aric D. Parnes Katayoon Goodarzi James I. Weitzman Jean M. Connors David J. Kuter 《Haematologica》2021,106(4):1148
Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy treatment delays, dose reductions, and discontinuation. There is no US Food and Drug Administration (FDA)-approved agent available to manage CIT. This study retrospectively evaluated patients with CIT treated on institutional romiplostim treatment pathways at four US centers. The primary outcome was achievement of a romiplostim response (median on-romiplostim platelet count ≥75x109/L and ≥30x109/L above baseline). Secondary outcomes included time to platelet count ≥100x109/L and rates of the following: platelet count <100×109/L, platelet count <75x109/L, platelet count <50x109/L, thrombocytosis, chemotherapy dose reduction/treatment delay, platelet transfusion, bleeding, and thromboembolism. Multivariable regression was used to identify predictors of romiplostim non-response and compare weekly dosing with intracycle/intermittent dosing. A total of 173 patients (153 solid tumor, 20 lymphoma or myeloma) were treated, with 170 (98%) receiving a median of four (range: 1-36) additional chemotherapy cycles on romiplostim. Romiplostim was effective in solid tumor patients: 71% of patients achieved a romiplostim response, 79% avoided chemotherapy dose reductions/treatment delays, and 89% avoided platelet transfusions. Median per-patient platelet count on romiplostim was significantly higher than baseline (116x109/L vs. 60x109/L; P<0.001). Bone marrow (BM) tumor invasion, prior pelvic irradiation, and prior temozolomide exposure predicted romiplostim non-response. Bleeding rates were lower than historical CIT cohorts and thrombosis rates were not elevated. Weekly dosing was superior to intracycle dosing with higher response rates and less chemotherapy dose reductions/treatment delays/bleeding; intracycle dosing had an incidence rate ratio (IRR) for dose reduction/treatment delay of 3.00 (95%CI: 1.30-6.91; P=0.010) and an IRR for bleeding of 4.84 (95%CI: 1.18-19.89, P=0.029) compared with weekly dosing. Blunted response (10% response rate) was seen in non-myeloid hematologic malignancy patients with BM involvement. In conclusion, romiplostim was safe and effective for CIT in most solid tumor patients. 相似文献
60.
Davide Castagno MD PhD Paolo Di Donna MD Iacopo Olivotto MD Antonio Frontera MD Leonardo Calò MD Marco Scaglione MD Anna Arretini MD Matteo Anselmino MD PhD Carla Giustetto MD Gaetano Maria De Ferrari MD Franco Cecchi MD Michel Haissaguerre MD Fiorenzo Gaita MD 《Journal of cardiovascular electrophysiology》2021,32(3):657-666